Antiviral treatment of recurrent hepatitis C after liver transplantation: The need for a multifaceted approach

Hepatology

Volumn 41, Issue 3, 2005, Pages 436-438

  Samuel, Didier ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

OKT 3; PEGINTERFERON; REBETRON; RIBAVIRIN;

ANEMIA; ANTIVIRAL ACTIVITY; CHOLESTATIC HEPATITIS; CYTOPATHOGENIC EFFECT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; GENOTYPE; GRAFT REJECTION; HEPATITIS C; HUMAN; IMMUNE RESPONSE; JAUNDICE; LEUKOPENIA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT INFECTION; THROMBOCYTOPENIA; TREATMENT INDICATION; VIRUS LOAD;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; RECURRENCE;

EID: 14244252179     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20623     Document Type: Editorial

References (32)

1. Liver Transplant Registry - ELTR. Registry for the European liver transplant association, data analysis, 05/1968-12/2000. Available at: http:// www.eltr.org.
2. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896.
3. Féray C, Caccamo L, Alexander GJM, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999;117:619-25.
4. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. HEPATOLOGY 1999;29:250-256.
5. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation increase in recent years. J Hepatol 2000;32:673-684.
6. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. HEPATOLOGY 2000;32:852-858.
7. McCaughan GW, Zekry A. Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 2004;40;368-374.
8. Doughty AL, Painter DM, McCaughan GW. Post-transplant quasi-species pattern remains stable over time in patients with recurrent cholestatic hepatitis due to hepatitis C virus. J Hepatol 2000;32:126-134.
9. Gane E, Naoumov N, Qian K, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;110:167-177.
10. Di Martino V, Saurini F, Samuel D, Gigou M, Dussaix E, Reynes M, et al. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. HEPATOLOGY 1997;26:1343-1350.
11. Féray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995;108:1088-1096.
12. Gigou M, Roque-Afonso AM, Falissard B, Penin F, Dussaix E, Féray C. Genetic clustering of hepatitis C virus strains and severity of recurrent hepatitis after liver transplantation. J Virol 2001;75 :11292-11297.
13. Rifai K, Sebagh M, Karam, V, Saliba F, Azoulay D, Adam R, et al. Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. J Hepatol 2004;41:446-453.
14. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. HEPATOLOGY 2002;36:202-210.
15. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002;51:248-252.
16. Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, et al. A model to predict severe HCV-related liver disease following liver transplantation. HEPATOLOGY 2003;38:34-41.
17. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. HEPATOLOGY 1995;21:30-34.
18. Everson G, Trouillot T, Trotter J, Halprin A, McKinley C, Fey B. Treatment of decompensated cirrhotics with a low-accelerating dose regimen (LADR) of interferonalpha-2b plus ribavirin: safety and efficacy [Abstract]. HEPATOLOGY 2001;32(Suppl 1):595.
19. Forns X, Garcia-Retortillo M, Serrano T, Feliu M, Suarex F, De la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003;39:389-393.
20. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. HEPATOLOGY 2002;35:680-687.
21. Féray C, Samuel D, Gigou M, Paradis V, David MF, Lemonnier C, et al. An open trial of Interferon alfa recombinant for hepatitis C after liver transplantation : antiviral effects and risk of rejection. HEPATOLOGY 1995;22:1084-1089.
22. Gane EJ, Lo SK, Riordan SM, Portmann BC, Lau JYN, Naoumov NV, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. HEPATOLOGY 1998;27:1403-1407.
23. Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver transplantation : a non randomized trial of interferon alpha alone versus interferon alpha and ribavirin. Liver Transpl 2001;10:863-869.
24. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliot M, Baulieux J, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. HEPATOLOGY 1997;26:500-504.
25. Lavezzo B, Franchello A, Smedile A, David E, Barbui A, Torrani M, et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alpha 2b with ribavirin. J Hepatol 2002;37:247-252.
26. Samuel D, Bizollon T, Féray C, Roche B, Si Ahmed SN, Lemonnier C, et al. Interferon alfa 2b plus ribavirin in patients with recurrent HCV infection after liver transplantation: a randomized study. Gastroenterology 2003;124:642-650.
27. Dumortier J, Scoazec JY, Chevallier P, Boillot O. treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alf-2b and ribavirin combination. J Hepatol 2004;40:669-674.
28. Rodriguez-Luna H, Khatib A, Shrama P, De Petris G, Williams JW, Ortiz J, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004;77:190-194.
29. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana R, Reilly C, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. HEPATOLOGY 2005;41:289-298.
30. Bizollon T, Ahmed SNS, Radenne S, Chevallier M, Parvaz P, Guichard S, et al. Long-term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003;52:283-287.
31. Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004;10:859-867.
32. Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, SentjensRE, Calleja JL, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis genotype 1 patients. Gastroenterology 2004;127:1347-1355.